{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BG505",
    "query": {
      "intervention": "BG505"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T09:42:33.488Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03783130",
      "title": "Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Prevention",
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "VRC-HIVRGP096-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum Adjuvant",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-03-07",
      "completion_date": "2020-06-24",
      "has_results": true,
      "last_update_posted_date": "2021-08-12",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783130"
    },
    {
      "nct_id": "NCT04224701",
      "title": "A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "ALL",
        "summary": "18 Years to 51 Years"
      },
      "enrollment_count": 48,
      "start_date": "2020-08-01",
      "completion_date": "2023-08-02",
      "has_results": false,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • New York, New York",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04224701"
    },
    {
      "nct_id": "NCT03699241",
      "title": "A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 SOSIP.664 gp140, adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-12-03",
      "completion_date": "2023-07-11",
      "has_results": false,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699241"
    },
    {
      "nct_id": "NCT05217641",
      "title": "A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 MD39.3 mRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BG505 MD39.3 gp151 mRNA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BG505 MD39.3 gp151 CD4KO mRNA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 108,
      "start_date": "2022-02-11",
      "completion_date": "2027-06-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217641"
    },
    {
      "nct_id": "NCT05471076",
      "title": "Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "426c.Mod.Core-C4b 30 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "426c.Mod.Core-C4b 100 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "426c.Mod.Core-C4b 300 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "BG505",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2022-08-22",
      "completion_date": "2026-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05471076"
    },
    {
      "nct_id": "NCT06267872",
      "title": "A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "CD4BS CH505M5 Pr-NP1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CH505TF chTrimer",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF (labeled as AP 60-702)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum Hydroxide Suspension (Alum)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACU-026-001-1 (labeled as empty LNP)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-10-07",
      "completion_date": "2026-09-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Nashville, Tennessee",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06267872"
    },
    {
      "nct_id": "NCT04177355",
      "title": "Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 SOSIP.664 gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CpG 1018",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-LSQ",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum (Aluminum Hydroxide Suspension)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 127,
      "start_date": "2020-01-13",
      "completion_date": "2024-11-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177355"
    },
    {
      "nct_id": "NCT05470400",
      "title": "A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "FP conjugate vaccine (25 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FP conjugate vaccine (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 6931 (100 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 6931 (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571 (200 mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571 (100 mcg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-08-15",
      "completion_date": "2024-01-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-02T09:42:33.488Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05470400"
    }
  ]
}